Opiant Pharmaceuticals (NASDAQ:OPNT) Rating Increased to Buy at ValuEngine
Other equities research analysts also recently issued research reports about the stock. Northland Securities reiterated a buy rating and issued a $42.00 target price on shares of Opiant Pharmaceuticals in a research report on Friday, May 1st. TheStreet downgraded shares of Opiant Pharmaceuticals from a c- rating to a d+ rating in a research report on Monday, April 6th.
Shares of NASDAQ:OPNT traded up $0.21 during mid-day trading on Thursday, hitting $9.13. The stock had a trading volume of 48,240 shares, compared to its average volume of 166,642. The company has a market cap of $38.89 million, a PE ratio of 4.39 and a beta of 0.78. Opiant Pharmaceuticals has a 12-month low of $8.05 and a 12-month high of $18.23. The company’s 50 day moving average is $10.19 and its 200-day moving average is $11.56.
Several institutional investors have recently added to or reduced their stakes in the company. Morgan Stanley lifted its holdings in shares of Opiant Pharmaceuticals by 27.8% during the 1st quarter. Morgan Stanley now owns 4,542 shares of the technology company’s stock worth $44,000 after acquiring an additional 989 shares during the period. Advisor Group Inc. lifted its holdings in Opiant Pharmaceuticals by 43.5% during the 4th quarter. Advisor Group Inc. now owns 6,600 shares of the technology company’s stock valued at $96,000 after purchasing an additional 2,000 shares during the last quarter. Advisor Group Holdings Inc. bought a new position in Opiant Pharmaceuticals during the 1st quarter valued at about $45,000. Acadian Asset Management LLC lifted its holdings in Opiant Pharmaceuticals by 439.7% during the 1st quarter. Acadian Asset Management LLC now owns 8,128 shares of the technology company’s stock valued at $79,000 after purchasing an additional 6,622 shares during the last quarter. Finally, Alambic Investment Management L.P. bought a new position in Opiant Pharmaceuticals during the 1st quarter valued at about $147,000. Institutional investors and hedge funds own 25.27% of the company’s stock.
About Opiant Pharmaceuticals
Opiant Pharmaceuticals, Inc, a specialty pharmaceutical company, develops pharmacological treatments for substance use, addictive and eating disorders. The company offers NARCAN nasal spray, a treatment to reverse opioid overdoses. Its pipeline of product candidates includes treatments for eating disorders, including bulimia nervosa and binge eating disorders, alcohol use disorders, a long term treatment to prevent relapse for patients with opioid use disorders, cocaine use disorders, and a heroin vaccine.
Featured Story: Differences Between Momentum Investing and Long Term Investing
To view ValuEngine’s full report, visit ValuEngine’s official website.
Receive News & Ratings for Opiant Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Opiant Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.